Tecentriq 1,200 MG/20 ML vial 20ML
Ended Awarded Last action
- Contract number
- SPE2DR26FSQS4
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $27,644
Award facts
- Contract value 100% obligated
- $27,644.48 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency issued a delivery order valued at $27,644.48 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Tecentriq (atezolizumab) 1,200 mg/20 mL vials. This firm fixed-price delivery order, issued on January 20, 2026, with an ultimate completion date of February 10, 2026, was awarded without a set-aside designation, demonstrating the contractor's competitive capability in unrestricted federal procurement. The order falls under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, which carries a ceiling value of $499,999,999 through December 31, 2036.
DMS Pharmaceutical Group has established itself as a critical supplier within the Department of Defense's pharmaceutical supply chain, leveraging its small business status and established performance record across multiple therapeutic categories. As an authorized vendor under the $30.3 billion PPV-G GEN V acquisition strategy, the company supplies an extensive portfolio of branded and generic prescription medications, biologics, vaccines, and medical consumables to military healthcare facilities. This delivery order for Tecentriq, an oncology treatment used in cancer care, exemplifies the company's role in providing specialized pharmaceutical products essential to Department of Defense medical operations.
Quick answers
Who was awarded contract SPE2DR26FSQS4?
SPE2DR26FSQS4 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on January 20, 2026.
How much is contract SPE2DR26FSQS4 worth?
The government has obligated $27,644 on SPE2DR26FSQS4.
Is contract SPE2DR26FSQS4 an order under another contract?
Yes. SPE2DR26FSQS4 is a delivery order under SPE2DR25D9348, an indefinite delivery contract.
Was contract SPE2DR26FSQS4 competed?
The extent of competition for SPE2DR26FSQS4 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award